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There has been increased detection of incidental AVMs as result of the frequent use of advanced imaging techniques. The natural
history of AVM is poorly understood and its management is controversial. This review provides an overview of the epidemiology,
pathophysiology, natural history, clinical presentation, diagnosis, and management of AVMs. The authors discussed the imaging
techniques available for detecting AVMs with regard to the advantages and disadvantages of each imaging modality. Furthermore,
this review paper discusses the factors that must be considered for themost appropriate management strategy (based on the current
evidence in the literature) and the risks and benefits of each management option.
1. Introduction
AVMs are abnormalities of the intracranial vessels that con-
stitute a connection between the arterial and venous systems
and lack an intervening capillary bed. Hemorrhagic presen-
tation of AVM is associated with significant morbidity and
mortality; it is an independent predictor of future hemor-
rhage. The gold standard for diagnosis of AVM is cerebral
angiography. However, the evolution of noninvasive imaging
techniques has led to the increased diagnosis of unruptured
AVM which now presents with new challenges with regard
to their management. This review paper provides a compre-
hensive review of the literature with presentation of the risks
and benefits of the differentmanagement options available for
AVM such as medical management, microsurgical resection,
stereotactic radiotherapy, and endovascular embolization.
Furthermore, the clinical presentation of patients with AVM
and how it relates to the preferred management option are
discussed in detail.
2. Epidemiology
Approximately 2% of AVMs are multiple and the remainder
are solitary [1]. According to reports, 0.1% of the population
harbors an AVM [2, 3]. Both sexes are affected equally.
AVMs are the leading cause of nontraumatic intracerebral
hemorrhage in people less than 35 years old [4]. Most lesions
reach attention in patients in their 40’s and 75% of the
hemorrhagic presentations occur before the age of 50 years
[2]. According to autopsy studies, only 12% of AVMs become
symptomatic during life [5].
3. Pathology and Pathophysiology
AVMs have three components: feeding arteries, nidus, and
draining veins [6]. The gross features of an AVM include the
presence of single or multiple direct arteriovenous connec-
tions that permit high-flow arteriovenous shunting through
small feeding arteries that lack a muscularis layer and the
absence of a capillary bed. Consequently, this high-flow shunt
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can produce structural changes in the feeding and draining
vessels which results in arterial smooth muscle hyperplasia
associated with fibroblasts and connective tissue elements
known as fibromuscular cushions [6]. The microscopic fea-
tures of AVMs are variable and depend on the portion of
the lesion that is sampled. The venous elements have thin
collagenous walls and the arterial feeders have muscular
elastic walls.The parenchymal elements within theAVM tend
to be hemosiderin stained, gliotic, and nonfunctional. Some
lesions may have vascular or interstitial calcification [7].
4. Natural History
AVMs are congenital lesions that occur sporadically. The
familial incidence of brain AVMs is rare, and only a few
reported cases in the literature; however there is an asso-
ciation with other abnormalities like Osler-Weber-Rendu
disease and Sturge-Weber syndrome [8, 9]. Cerebral AVMs
account for 1.4% to 2% of hemorrhagic strokes [10, 11]. The
estimated prevalence of AVM varies from less than 10 to 18
per 100,000 [12, 13]. Brain AVMs are found incidentally on
0.05% of brain MRI screens [14].
Thenatural history of asymptomatic brainAVMs remains
poorly understood and conflicting information can be found
on symptomatic lesions in the literature. Although scientists
have not reliably identified anatomic predictors, spontaneous
obliteration may be more likely to occur in small AVMs (less
than 2.5 cm) that present with hemorrhage and have fewer
arterial feeders [15].This phenomenon is more likely to occur
with AVMs drained by a single draining vein and associated
with smaller AVMs and a hemorrhagic presentation [16].
5. Clinical Presentation
Cerebral AVMs may present with intracranial hemorrhage,
seizures, headaches, and long-term disability; the most com-
mon presenting symptoms are hemorrhage and seizures [17].
5.1. Intracranial Hemorrhage. The annual incidence of hem-
orrhage of unruptured and untreated brain AVMs is of 2%
to 4% with approximately 38% to 71% of patients with brain
AVMs presenting with intracranial hemorrhage [17]. There
are conflicting data in regard to association of age and risk of
hemorrhage; however, the initial presentation of hemorrhage
most commonly occurs in patients between the ages of 20 and
40 [18, 19]. Although conflicted data exists in regard to the
effect of gender on hemorrhage, evidence seems to support
no effect of gender on the risk of hemorrhage [20, 21].
There is data to suggest that hemorrhagic presentation
is a significant independent predictor of future hemorrhage.
Ondra and colleagues [22] over a 24-year period had a
prospectively followed cohort of unoperated symptomatic
patients with brain AVMs and found a mean time interval
of 7.7 years between initial presentation and subsequent
hemorrhage. Brown Jr. and colleagues [2] found that the risk
of subsequent hemorrhage fell from 32.9% during the first
year to 11.3% per year in subsequent years among patients
with hemorrhage as the initial presentation. A study from
Toronto [17] found an annual risk of hemorrhage of 9.65%
during the first year and 3.67% after 5 years from the initial
hemorrhagic presentation.
Other potential risk factors for hemorrhage include
(1) AVM with exclusively deep venous drainage (typically
defined as drainage through the periventricular, galenic, or
cerebellar pathways), (2) AVM associated with aneurysms,
(3) AVMs that are deep in location, and (4) AVM that is
infratentorial in location [17]. Brain AVMs are heterogeneous
since each AVM’s unique feature of microanatomy and
vascular architecture may provide a unique clinical outcome.
The risk of hemorrhage varies from 0.9% per year in patients
without risk factors like hemorrhagic presentation, deep
AVM location, or deep venous drainage and may be as
high as 34.4% in patients with these factors [23, 24]. In a
prospective study of 678 patients, the overall hemorrhage rate
of brain AVMswith associated aneurysmswas 6.93% per year
comparedwith 3.99% per year for patients without associated
aneurysms [17].The risk of hemorrhage remains present until
complete AVM obliteration; therefore partial endovascular
embolization of an AVM does not completely reduce the risk
of hemorrhage to zero [17].
5.2. Seizures. Seizures occur in about 18% to 40% of brain
AVMswith favorable response to treatmentwith antiepileptic
drugs [17, 25].The type of seizure most commonly associated
with AVMs is generalized seizures (30%) [26]. There is no
significant association of hemorrhage with initial presenta-
tion with seizure, focal neurological deficits, or headaches as
demonstrated by Brown Jr. et al. [2]. Furthermore, patients
presenting with seizure are not more likely to suffer an AVM
rupture during follow-up [17]. For instance, in the Toronto-
based prospective study of 678 patients, the hemorrhage rate
for patients presenting with seizure was 4.16% per year, which
was close to the rate for the entire cohort (4.61%) [17].
5.3. Headache. Headaches occur in approximately 5% to
14% of patients with brain AVMs and these headaches are
not distinctive. They can be unilateral or bilateral and can
have migrainous features with and without aura [22, 26].
Currently, there are no studies to evaluate the rate of response
to pharmacologic treatment and AVM obliteration.
5.4. Focal Neurologic Deficits (FNDs). Focal neurologic
deficits (FNDs) occur in 1% to 40% of patients with brain
AVMs [3]. Only 5% to 15%manifest progressive deficits unre-
lated to hemorrhage [6].Thepathophysiology of these deficits
is multifactorial and includes vascular steal phenomenon
and/or venous hypertension.The vascular steal phenomenon
is centered around the perinidal arterial steal, which results
from the high-flow shunting through the AVM and leads to
low blood pressure in the feeding arteries and surrounding
brain tissue [27]. Furthermore, venous dilatation may lead
to mass effect and compression of brain tissue therefore
resulting in FNDs [28]. The Columbia AVM Database (with
5,735 patients) found an independent association of FND
with increasing age, female gender, deep brain location, and
venous ectasia without any association with lobar location,
size, arterial supply, or venous drainage pattern [28].
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6. Imaging
Conventional cerebral angiography is the gold standard in
the evaluation of AVM angioarchitecture, and it shows the
following essential features: the feeding arteries, location of
nidus, draining veins, morphology, presence, and location
of associated aneurysms, venous varices, and vasculopathic
stenotic segments on arteries and veins. These features are
important because they are commonly used for treatment
planning [29]. One of the important angiographic features is
the visualization of the AVM during the arterial phase of an
early draining vein since this feature confirms the presence
of an arteriovenous shunt. Intraventricular hemorrhage as
a result of AVM rupture is secondary to the apex of the
nidus (seen as awedge-shaped arrangement of tangled vessels
on cerebral angiography) projecting toward the ventricular
surface. Furthermore, in the presence of hemorrhage, mass
effect can be appreciated on an angiography. It is important
to note that a thrombosed AVM may not be detected on a
cerebral angiography.
Other imaging modalities which are often the initial
studies used to evaluate symptoms that are not specific to
AVMs include CT, CT angiography, MRI, and magnetic
resonance angiography. However, these imaging techniques
are limited in their sensitivity and ability to provide detailed
imaging of AVM architecture [29]. Each imaging technique
provides its own unique strength: CT angiography provides
better vascular detail of AVMs, whereas MRI and mag-
netic resonance angiography provide greater visualization of
surrounding structures adjacent to the nidus. Furthermore,
MRI can detect thrombosed vessels as hyperintense signals
and show any associated hemorrhage at various stages of
evolution. T2-weighted and GRE sequences are the most
sensitive to breakdown products. MRI can be important for
preoperative planning because it allows for an appropriate
surgical approachwhile demonstrating the relationship of the
AVM and important parenchymal structures.
7. Management
An important factor that must be considered during the
treatment decision-making process is to compare the risks
of all treatment modalities against the natural history risks
of AVMs. Management of cerebral AVMs includes obser-
vation with medical management, microsurgical resection,
stereotactic radiotherapy, and endovascular embolization.
Invasive treatment modalities are the reasonable choice for
ruptured cerebral AVMs due to the high rate of morbidity
and mortality, and the goal of treatment is eradication of
the AVM. The factors that dictate treatment options (which
may include single or multimodal therapy) are operator skill,
AVM size and location, surgical or endovascular accessibility,
venous drainage, and presence of high-risk features, such as
a feeding artery aneurysm [30].
However, the appropriate treatment modalities for
unruptured AVMs present a challenging clinical dilemma
because of a poorly defined natural history and the seemingly
low annual hemorrhage rates. This clinical conundrum led
to the development of ARUBA which aims to compare the
Table 1: Spetzler-Martin Grading Scale for AVMs.
Characteristic Number of points assigned
Size of AVM
Small (<3 cm) 1 point
Medium (3–6 cm) 2 points
Large (>6 cm) 3 points
Location
Noneloquent site 0 points
Eloquent site∗ 1 point
Pattern of venous drainage
Superficial only 0 points
Deep component 1 point
∗Sensorimotor, language, visual cortex, hypothalamus, thalamus, internal
capsule, brain stem, cerebellar peduncles, or cerebellar nuclei.
natural history with modern multimodal therapy. ARUBA
(a randomized trial of unruptured brain arteriovenous
malformations) was the first randomized controlled trial to
evaluate surgical intervention versus medical management
for unruptured cerebral AVMs. However, errors in study
design, execution, short length of follow-up, and a relative
lack of information regarding the treatment arm and the
enrollment process invalidate the authors’ conclusions [30].
7.1. Observation with Medical Management. Conservative
treatment is considered for management of asymptomatic
AVMs. Furthermore, it may include management of asso-
ciated symptoms, general medical care, and surveillance
imaging of an AVM. Time intervals for surveillance imaging
are not well defined and may include MRI brain imaging
annually or biennially. Specific medical care may include
management of hypertension, headache, and seizures. Sim-
ilar outcomes in seizure frequency have been reported in
an observational study comparing conservative management
and AVM treatment [31].
7.2. Microsurgical Resection. In 1986, Spetzler and Martin
introduced a grading system for AVMs based on the nidus
size, location in relation to eloquent cortex, and venous
drainage pattern (see Table 1); site includes sensorimotor, lan-
guage, visual cortex, hypothalamus, thalamus, internal cap-
sule, brainstem, cerebellar peduncles, and cerebellar nuclei
[32]. The Spetzler-Martin Scale is used to estimate the risk
of surgical resection of an AVM with higher grades being
associated with greater surgical morbidity andmortality [33].
Microsurgery is the gold standard for definitive treatment
of AVMs. Microsurgical excision of the AVM involves a
craniotomy, careful dural opening with circumferential nidus
dissection until complete AVM resection is achieved. Postop-
erative angiography is performed to demonstrate complete
AVM excision. The advantage of microsurgical resection is
the high rate of complete obliteration, while the limitations
of this approach include anatomic accessibility, edema from
retraction, intraoperative rupture, resection of normal brain
tissue, and feeding vessel thrombosis. Microsurgical adjuncts
to help facilitate a better surgical outcome include the
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use of mapping, corticography, stimulation, and functional
MRI [34]. A meta-analysis comprising 2425 patients treated
between 1990 and 2000 showed a surgical mortality of 3.3%
and a permanent postoperative morbidity of 8.6%, with
an increasing morbidity-mortality rate associated with an
increasing Spetzler-Martin grade [35].
The cure of AVM in adults is definitive with complete
microsurgical resection and angiographic confirmation of
obliteration. However, AVMs in children are more dynamic
and may have the ability to regenerate after negative angio-
graphic studies [36].
7.3. Stereotactic Radiosurgery. Radiosurgery involves the
delivery of localized high-dose radiation to the AVM to
induce a vascular injury, which leads to gradual sclerosis of
the blood vessels with eventual obliteration over a period of
2 to 3 years. Successful treatment with radiosurgery depends
on AVM size, grade, location, angioarchitecture, density of
the nidus, and radiation dosage. AVMs smaller than 3.5 cm
are ideal for obliteration [37]. The time from treatment to
obliteration ranges from 2 to 3 years during which the patient
has no protection fromhemorrhage because of the delay from
the effects of radiation. It was reported by Hernesniemi and
colleagues [38] that the risk of hemorrhage during the initial
2 years after radiosurgery was 4.8% per year, which compares
favorably with the natural history of AVMs.
However, this is less favorable with microsurgical resec-
tion. About 2 to 5 years after radiosurgery, the risk of hemor-
rhage is slightly higher at 5.0% per year but not significantly
different from the natural history of AVMs. However, it
should be noted that Pikus and colleagues demonstrated
that microsurgically treated grade I to III AVMs had higher
incidence of obliteration with statistically significant fewer
postoperative hemorrhages, neurological deficits, and deaths
when compared with stereotactic radiosurgery [39]. A mul-
ticenter analysis of 1255 patients receiving radiotherapy
reported 102 (8%) patients developed a neurologic deficit after
radiosurgery [40].
The advantages of radiosurgery include a noninvasive
therapy and reasonable obliteration rates. The disadvantages
of radiosurgery include the risk of bleeding during the latency
of 1 to 2 years, neurologic deficits from edema and necrosis
of normal brain tissue, and individual sensitivity to radiation
and unknown long-term outcome.
7.4. Endovascular Embolization. Endovascular treatment of
brain AVMs involves the delivery of liquid embolics, such
as n-butyl cyanoacrylate and ethylene vinyl alcohol copoly-
mer (Onyx) and platinum embolic coils via superselective
catheterization with flow-guided ultrathin microcatheters.
Often times, it is performed as preoperative embolization
to surgical resection or in conjunction with stereotactic
radiotherapy. Preoperative embolization can reduce the size
of an AVM for microsurgical excision, and it has been shown
to have acceptable rates of clinically significant complications
(approximately 6.5%) [41].
Embolization may be performed as an adjunctive treat-
ment to reduce the size of the AVM before radiosurgery.
In certain cases, small malformations may be completely
obliterated by embolization alone and large AVMs may
undergo near-complete obliteration. Furthermore, palliative
embolization may be used in selected cases to stabilize
progression of neurologic deficits or attempt seizure control
in cases where AVMs are not amenable to microsurgical
excision or radiotherapy.
The advantages of endovascular therapy include a mini-
mally invasive approach, possible immediate occlusion, and
intraprocedure angiographic evaluation. The disadvantages
of endovascular therapy include incomplete embolization,
unintended vessel embolization, intracranial hemorrhage,
and normal perfusion pressure breakthrough, leading to
edema or hemorrhage [42].
8. Conclusion
The increasing use of advance imaging techniques will
increase the incidence of asymptomatic AVMs. At the present
moment, we do not fully understand the natural history of
AVMs to precisely predict which AVMs will likely bleed and
what the most appropriate optimal treatment option will be,
single or multimodal therapy. In the future, we certainly
need well designed randomized controlled trials to compare
different treatment modalities and their outcomes.
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